Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ipilimumab and Nivolumab in the Treatment of malignant Pleural Mesothelioma: a Phase II study.

Next Previous
X
Search
Trial Profile

Ipilimumab and Nivolumab in the Treatment of malignant Pleural Mesothelioma: a Phase II study.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Malignant-mesothelioma
  • Focus Therapeutic Use
  • Acronyms INITIATE

    • Most Recent Events

    • 01 Nov 2022 Results of an analysis assessing possible impact of subgroups of immune cells in subsequent tumor biopsies of patients treated with ICIs from two clinical studies: NCT02497508 (n=34) and NCT03048474 (n=36) published in the Lung Cancer
    • 17 Nov 2021 Results published in the Journal of Thoracic Oncology
    • 01 Jun 2021 Results assessing the accuracy of exhaled breath analysis using electronic technology (eNose) for discriminating between responders to ICI and non-responders, published in the European Journal of Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top